Phase 2 RCT: Efficacy and safety of Deucravacitinib, a selective TYK2 inhibitor, in psoriatic arthritis.

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis – Annals of Rheumatic Diseases

Commentary on Twitter

Phase II trial: selective TYK2 inhibitor deucravacitinib in 203 patients with PsA:
▶️ Prim outcome met: ACR-20 response deucravacitinib 6 mg daily 52.9% / 12 mg daily 62.7% vs placebo 31.8% at week 16
▶️ Fig: adjusted mean change from baseline in HAQ-DIhttps://t.co/YR1ZbfF0gy pic.twitter.com/WNCjEGpj27

— ARD & RMD Open (@ARD_BMJ) March 4, 2022